PPARgamma and atherosclerosis: effects on cell growth and movement.
about
Insulin Resistance and Endothelial Dysfunction Constitute a Common Therapeutic Target in Cardiometabolic DisordersPGC-1alpha is a key regulator of glucose-induced proliferation and migration in vascular smooth muscle cellsInhibition of phosphatidylinositol 3-kinase/Akt signaling attenuates hypoxia-induced pulmonary artery remodeling and suppresses CREB depletion in arterial smooth muscle cellsPGC-1alpha inhibits oleic acid induced proliferation and migration of rat vascular smooth muscle cells.Effect of PPARgamma inhibition on pulmonary endothelial cell gene expression: gene profiling in pulmonary hypertension.PPARγ negatively regulates T cell activation to prevent follicular helper T cells and germinal center formation.The antiinflammatory effect of laminar flow: the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolaseVasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitroEffect of PPARγ inhibition during pregnancy on posterior cerebral artery function and structureCarotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetesAntidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.Understanding insulin resistance. What are the clinical implications?Reduction of cardiovascular morbidity and mortality in type 2 diabetes. A rational approach to hypoglycemic therapy.Peroxisome proliferator-activated receptors and cardiovascular remodeling.Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgammaDetermination of PPARγ activity in adipose tissue and spleen.Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity.Inflammation in coronary artery disease: potential role for immunomodulatory therapy.Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.The adaptation of the cerebral circulation to pregnancy: mechanisms and consequencesEffect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.Combining beta-adrenergic and peroxisome proliferator-activated receptor gamma stimulation improves lipoprotein composition in healthy moderately obese subjectsStrain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-IRosiglitazone modulates pigeon atherosclerotic lipid accumulation and gene expression in vitro.A rapid, PPAR-gamma-dependent effect of pioglitazone on the phosphorylation of MYPT.Pioglitazone Ameliorates Smooth Muscle Cell Proliferation in Cuff-Induced Neointimal Formation by Both Adiponectin-Dependent and -Independent Pathways.Distinct functions of vascular endothelial and smooth muscle PPARgamma in regulation of blood pressure and vascular tone.Laminar shear stress up-regulates the expression of stearoyl-CoA desaturase-1 in vascular endothelial cells.PPARs and their effects on the cardiovascular system.Restenosis after PCI. Part 2: prevention and therapy.Urolithin A attenuates ox-LDL-induced endothelial dysfunction partly by modulating microRNA-27 and ERK/PPAR-γ pathway.Peroxisome proliferator-activated receptors in cardiac energy metabolism and cardiovascular disease.Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formationAnti-angiogenic action of PPARγ ligand in human umbilical vein endothelial cells is mediated by PTEN upregulation and VEGFR-2 downregulation.Paracrine regulation of angiogenesis and adipocyte differentiation during in vivo adipogenesisInflammatory responses in the atria: should they stay or should they go?Acute insulin resistance stimulates and insulin sensitization attenuates vascular smooth muscle cell migration and proliferation.Mildly oxidised LDL induces more macrophage death than moderately oxidised LDL: roles of peroxidation, lipoprotein-associated phospholipase A2 and PPARgamma.Long-term effects of the PPAR gamma activator pioglitazone on cardiac inflammation in stroke-prone spontaneously hypertensive rats.PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.
P2860
Q26740443-0216AF51-EA88-48CB-90BF-EFA1C04B8408Q28581042-32B51E12-2D8B-4A94-BA0D-6F67E7F74CD3Q28581058-2463D010-0E55-4839-A300-58AAB891B5FEQ33305208-F5551E33-D277-4FC7-91DA-C82CA469299FQ33593476-5A3AEFBA-372A-40B9-BCC6-115CC1792BDAQ33748674-8507CD1D-74C6-4B54-8EDE-5157BB9C2AE2Q34116662-5C02161F-6777-4914-A47A-D82554C6F869Q34576530-1C6F51FD-D19E-4839-88FB-9EDEB4F133E6Q34691864-126485DB-8240-4BE0-9627-26191CED9DFDQ34721194-7D1F8FCD-20F8-4C2E-8196-B22C58DEA5ACQ35596926-8829AB07-120B-4F1B-92FE-59B2E4D3770EQ35845733-14551FD9-1773-4EDF-A948-6A957D581D7FQ35847886-1D7E7BD9-1535-4F40-89ED-78AFFFF65A1DQ35890826-03C67ED9-F7BB-45D4-BEDB-61E9D961E22FQ35919761-35BD01B0-1B8A-4E75-9415-89D2DFA9953DQ36067481-322BB90D-3EC2-428F-AC1E-0D10EFA8BAD5Q36068458-DC58402E-490A-4FC2-9FFF-6EABA4B186AAQ36314881-B3049721-53F3-4A22-B32E-4AC032DFC5F9Q36578665-C27C7682-8CAC-41E3-890B-58193285008FQ36745113-44ADF54C-8E0B-4BC0-B56B-C5AF3D79EF6CQ36805400-CF4C49C9-4B0E-406C-92CF-44B121D02358Q37002299-4797CD0C-AF20-4617-A041-D6E499F8DC4FQ37125989-7560B6D1-99DA-4573-8C13-D4569E0E86C4Q37183777-3CA09D7A-D515-4F3D-82CC-80C0F48E855EQ37190320-E4912718-99A9-42FE-96F8-DFB04F830CAAQ37310692-28B6465B-08FE-422B-8A5E-419CA4AA5C1CQ37468639-0BFDC96E-F50D-4E16-AC18-0A76E0213E78Q37470957-33DD4E6B-5DB2-4D66-8466-DE7EEABAD21EQ37896654-8F534B32-211A-4985-A34D-F2DCFB782F86Q37944416-84AF54A4-279D-40B4-9E4B-E47A13B63926Q38779662-7D8FA3F9-09FA-42BA-953C-C2B346060787Q38817895-BC380FBF-BF21-4EAA-BC4C-DC5996DB79C5Q41932068-3FE57921-CFB2-46E4-958D-DD6CC0F8E9C3Q42491731-1737AF00-9ECD-46A4-B08D-219D29DA8ED1Q42574886-8313B614-8AE0-49A9-8A2A-E9E43412C904Q42694091-54E80951-DA83-45E5-A59A-8029641DC57EQ43042437-6F3B5CBA-2F41-4741-819B-350E1057D083Q44612499-1A6E18F5-F130-495A-8F12-C23BCC54C84AQ45220355-7B2331BF-C770-45E8-A732-A700EDE76B68Q46006542-201E1FC4-9A95-4E3D-9B8B-9037798C2159
P2860
PPARgamma and atherosclerosis: effects on cell growth and movement.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
PPARgamma and atherosclerosis: effects on cell growth and movement.
@ast
PPARgamma and atherosclerosis: effects on cell growth and movement.
@en
PPARgamma and atherosclerosis: effects on cell growth and movement.
@nl
type
label
PPARgamma and atherosclerosis: effects on cell growth and movement.
@ast
PPARgamma and atherosclerosis: effects on cell growth and movement.
@en
PPARgamma and atherosclerosis: effects on cell growth and movement.
@nl
prefLabel
PPARgamma and atherosclerosis: effects on cell growth and movement.
@ast
PPARgamma and atherosclerosis: effects on cell growth and movement.
@en
PPARgamma and atherosclerosis: effects on cell growth and movement.
@nl
P356
P1476
PPARgamma and atherosclerosis: effects on cell growth and movement.
@en
P304
P356
10.1161/HQ1201.100261
P407
P577
2001-12-01T00:00:00Z